Passer Ă  la version Pro

🌟 DĂ©couvrez toutes nos offres sur desktop ou tablette !

Global Antibody Production Market to Surpass USD 41.2 Billion by 2031 Amid Growing Biologics Demand and Technological Breakthroughs

[Boston, 4 June 2025] – Clearview Market Insights (CVMI) projects that the global antibody production market will grow from USD 18.1 billion in 2024 to USD 41.2 billion by 2031, achieving a robust compound annual growth rate (CAGR) of 12.6 percent. This expansion is driven by the increasing demand for monoclonal antibodies (mAbs), rapid biologics development pipelines, and ongoing innovation in cell-line engineering as well as continuous manufacturing.

“Antibodies have become foundational to modern medicine—from targeted cancer therapy to next-generation diagnostics,” said Dr. Ravi Chandra, lead biomanufacturing analyst at CVMI. “What was once a lab-scale tool has now matured into a multibillion-dollar industrial backbone supporting personalized healthcare, pandemic response, and global biosimilar growth.”

Request Sample @ https://clearviewmarketinsights.com/report-details/global-antibody-production-market/

Key Numbers

  • 2024 Market Value: USD 18.1 billion
  • 2031 Market Value: USD 41.2 billion
  • Seven-Year CAGR: 12.6 percent
  • Therapeutic Applications Share (2024): 53%
  • North America Market Share: 38%

Market Drivers

  • Rising Biologic Therapies
  • Contract Manufacturing Demand
  • Technological Advancements
  • Global Health Preparedness
  • Government Incentives

Company Highlights

  • Lonza launched Ibex® Design, reducing the timelines for clinical-scale antibody production by 40 percent.
  • Samsung Biologics has opened its fourth plant in Incheon, thereby doubling its antibody production capacity.
  • WuXi Biologics commenced development of a mega-facility in Singapore with modular POD-based architecture.
  • Thermo Fisher Scientific strengthened its biologics CDMO business through the acquisition of Belgium-based Henogen.

Regional Insights

  • North America: Dominates the market with advanced CDMO infrastructure and high biologic drug consumption.
  • Asia-Pacific: Fastest-growing region; China and India are scaling domestic production through government grants and tech transfers.
  • Europe: Hosts a strong biosimilar manufacturing base.
  • Latin America & MEA: Emerging interest in local antibody fill-finish and diagnostic assay development.

Technology Trends

  • AI-driven Bioprocessing
  • Modular Biomanufacturing
  • Cell-Line Optimization
  • Single-Use Systems

Milestones (2024–2025)

Quarter

Event

Impact

Q1 2024

Lonza launches Ibex® Design

40% faster process development cycle

Q2 2024

Samsung Biologics opens new facility

Global antibody production capacity up 25%

Q3 2024

Thermo Fisher expands CDMO services

Strengthens diagnostics-focused antibody supply

Q1 2025

WuXi Biologics breaks ground in Singapore

Modular bioproduction model enters APAC market

For more insights, visit https://clearviewmarketinsights.com/report-store  

 

About Clearview Market Insights

Clearview Market Insights is a global research and consulting firm that delivers forward-looking intelligence across more than 100 healthcare, biotechnology, and pharmaceutical markets. Our analysts synthesize real-time data, executive insights, and strategic models to support decision-making at the highest levels.

 

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369

 

Babafig 🌍 https://www.babafig.com